S. Thorlacius

发表

Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer

Kevin M. Bradley, D. Gudbjartsson, A. Sigurdsson, 2008, Nature Genetics.

Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

L. Kiemeney, U. Thorsteinsdóttir, K. Stefánsson, 2009, Nature Genetics.

Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer

D. Gudbjartsson, L. Kiemeney, J. Gulcher, 2007, Nature Genetics.

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer

A. Sigurdsson, L. Kiemeney, J. Gulcher, 2008, Nature Genetics.

p53 abnormalities and genomic instability in primary human breast carcinomas.

J. Eyfjörd, S. Thorlacius, M. Steinarsdóttir, 1995, Cancer research.

Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity

Ellen Kampman, Kari Stefansson, Torben Hansen, 2009, Nature Genetics.

Many sequence variants affecting diversity of adult human height

Bjarni V. Halldórsson, H. Stefánsson, A. Ingason, 2008, Nature Genetics.

Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes

D. Gudbjartsson, A. Sigurdsson, T. Blondal, 2007, Nature Genetics.

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

J. Hopper, D. Easton, P. Pharoah, 2003, American journal of human genetics.

Sequence variant on 8q24 confers susceptibility to urinary bladder cancer

Tony Fletcher, Paolo Vineis, Simonetta Guarrera, 2008, Nature Genetics.

Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

Jian Gu, Paolo Vineis, Simonetta Guarrera, 2009, Nature Genetics.

A variant associated with nicotine dependence, lung cancer and peripheral arterial disease

Daniel F. Gudbjartsson, Kari Stefansson, Gudmar Thorleifsson, 2008, Nature.

Study of a single BRCA2 mutation with high carrier frequency in a small population.

J. Eyfjörd, J. Jónasson, S. Thorlacius, 1997, American journal of human genetics.

BRCA 2 and p 53 Mutations in Primary Breast Cancer in Relation to Genetic Instability 1

S. Grétarsdóttir, J. Jónasson, S. Thorlacius, 2006 .

CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status

J. Jónasson, S. Thorlacius, J. Eyfjord, 2003, British Journal of Cancer.

BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability.

J. Eyfjörd, S. Grétarsdóttir, J. Jónasson, 1998, Cancer research.

TP53 abnormalities and genetic instability in breast cancer.

J. Eyfjörd, S. Grétarsdóttir, S. Thorlacius, 1995, Acta oncologica.

Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.

A. Børresen-Dale, C. Larsson, Å. Borg, 1998, Cancer research.

IF53 Mutations and Abnormal Staining in Breast Carcinomas Prognosis ~53 Protein Related to

S. Thorlacius, L. Tryggvadottir, 1995 .

The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds

J. Rommens, A. Thomas, M. Skolnick, 1996, Nature Genetics.

Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits

D. Gudbjartsson, A. Sigurdsson, Á. Jónasdóttir, 2008, Nature Genetics.

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types

Paolo Vineis, Giuseppe Matullo, Kari Stefansson, 2009, Nature Genetics.

A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes

J. Eyfjörd, S. Tavtigian, J. Jónasson, 1996, Nature Genetics.

ARTICLE The

M. Halldórsson, T. Rafnar, S. Thorlacius, 2006 .

Screening for germ line TP53 mutations in breast cancer patients.

S. Friend, E. Hovig, J. Eyfjörd, 1992, Cancer research.

Population-based study of risk of breast cancer in carriers of BRCA2 mutation

J. Struewing, J. Eyfjörd, S. Wacholder, 1998, The Lancet.

Prostate cancer progression and survival in BRCA2 mutation carriers.

Thorunn Rafnar, T. Rafnar, E. Jonsson, 2007, Journal of the National Cancer Institute.

BRCA2 mutation in Icelandic prostate cancer patients

J. Eyfjörd, K. Benediktsdottir, E. Jonsson, 1997, Journal of Molecular Medicine.

NPGRJ_NG_122 609..615

H. Stefánsson, A. Ingason, S. Steinberg, 2008 .

Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.

J. Eyfjörd, S. Thorlacius, A. L. Börresen, 1993, Cancer research.

BRCA2 mutation carriers, reproductive factors and breast cancer risk

J. Jónasson, S. Thorlacius, J. Eyfjord, 2003, Breast cancer research : BCR.

BRCA2mutation carriers, reproductive factors and breast cancer risk

J. Jónasson, S. Thorlacius, J. Eyfjord, 2003, Breast Cancer Research.

TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.

J. Eyfjörd, S. Thorlacius, J. Eyfjord, 1995, European journal of cancer.

The Icelandic Cancer Project – a population-wide approach to studying cancer

Jotun Hein, Violeta Calian, Thorunn Rafnar, 2004, Nature Reviews Cancer.

Linkage to BRCA2 region in hereditary male breast cancer

J. Jónasson, S. Thorlacius, J. Eyfjord, 1995, The Lancet.

TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains

E. Hovig, Å. Borg, J. Eyfjörd, 1995, Genes, chromosomes & cancer.

A population-based study on the familial aggregation of cutaneous malignant melanoma in Iceland.

T. Rafnar, J. Jónasson, S. Thorlacius, 2006, European journal of cancer.

BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.

T. Rafnar, K. Benediktsdottir, S. Thorlacius, 2004, European journal of cancer.

Male breast cancer in Iceland

B. Agnarsson, J. Jónasson, S. Thorlacius, 1996, International journal of cancer.

Intracellular metabolite profiling of platelets: evaluation of extraction processes and chromatographic strategies.

Ines Thiele, Bernhard Ø Palsson, B. Palsson, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

D. Easton, J. Hopper, D. Easton, 2005, Journal of Medical Genetics.

Monitoring metabolites consumption and secretion in cultured cells using ultra-performance liquid chromatography quadrupole–time of flight mass spectrometry (UPLC–Q–ToF-MS)

Ronan M. T. Fleming, Ines Thiele, Bernhard Ø. Palsson, 2011, Analytical and Bioanalytical Chemistry.

Recommendation for validation and quality assurance of non‐invasive prenatal testing for foetal blood groups and implications for IVD risk classification according to EU regulations

P. Bugert, S. Thorlacius, W. Lane, 2021, Vox sanguinis.

Evaluation of Association of HNF1B Variants with Diverse Cancers: Collaborative Analysis of Data from 19 Genome-Wide Association Studies

J. Murabito, M. McCarthy, E. Zeggini, 2010, PloS one.

Loss of heterozygosity at selective sites on chromosomes 13 and 17 in human breast carcinoma.

S. Thorlacius, J. Eyfjord, O. Jónasdóttir, 1991, Anticancer research.

Evaluation of Association of HNF1B Variants with Diverse Cancers: Collaborative Analysis of Data from 19 Genome-Wide Association Studies

Aleksandar, Manal M. Hassan, Shannon M. Lynch, 2010, PloS one.

Variants with Diverse Cancers : Collaborative Analysis of Data from 19 Genome-Wide Association Studies

J. Murabito, E. Zeggini, D. Gudbjartsson, 2010 .

Evaluation of Association of HNF 1 B Variants with Diverse Cancers : Collaborative Analysis of Data from 19 Genome-Wide Association Studies

J. Murabito, E. Zeggini, D. Gudbjartsson, 2010 .